COLOTTA, VITTORIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.846
EU - Europa 8.198
AS - Asia 5.834
SA - Sud America 848
Continente sconosciuto - Info sul continente non disponibili 223
AF - Africa 192
OC - Oceania 104
Totale 28.245
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.634
RU - Federazione Russa 2.603
IT - Italia 1.905
SG - Singapore 1.387
CN - Cina 1.342
VN - Vietnam 1.010
HK - Hong Kong 879
IE - Irlanda 829
SE - Svezia 739
BR - Brasile 686
PL - Polonia 468
KR - Corea 456
DE - Germania 357
UA - Ucraina 322
FI - Finlandia 287
FR - Francia 264
IN - India 250
GB - Regno Unito 212
CA - Canada 134
JP - Giappone 107
AU - Australia 99
JO - Giordania 87
AR - Argentina 80
BD - Bangladesh 70
NL - Olanda 67
ES - Italia 48
ID - Indonesia 46
TR - Turchia 43
ZA - Sudafrica 36
CI - Costa d'Avorio 35
MX - Messico 35
MA - Marocco 34
IQ - Iraq 32
SC - Seychelles 29
CH - Svizzera 23
PK - Pakistan 20
CO - Colombia 18
EG - Egitto 16
VE - Venezuela 14
EC - Ecuador 13
GT - Guatemala 12
PH - Filippine 12
TH - Thailandia 12
BE - Belgio 11
PY - Paraguay 11
AT - Austria 8
AZ - Azerbaigian 8
CL - Cile 8
EE - Estonia 8
CR - Costa Rica 7
IL - Israele 7
JM - Giamaica 7
NG - Nigeria 7
PE - Perù 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
EU - Europa 6
IR - Iran 6
MY - Malesia 6
SA - Arabia Saudita 6
AL - Albania 5
CZ - Repubblica Ceca 5
DK - Danimarca 5
KG - Kirghizistan 5
KZ - Kazakistan 5
PT - Portogallo 5
SN - Senegal 5
UY - Uruguay 5
AO - Angola 4
ET - Etiopia 4
HU - Ungheria 4
LB - Libano 4
LT - Lituania 4
NA - Namibia 4
NZ - Nuova Zelanda 4
BJ - Benin 3
DZ - Algeria 3
HN - Honduras 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
BZ - Belize 2
CG - Congo 2
GR - Grecia 2
KE - Kenya 2
MM - Myanmar 2
MU - Mauritius 2
SV - El Salvador 2
TW - Taiwan 2
AG - Antigua e Barbuda 1
AI - Anguilla 1
Totale 28.008
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.044
Ashburn 1.366
Singapore 962
Fairfield 845
Dublin 828
Hong Kong 722
Chandler 647
Warsaw 463
Jacksonville 460
Seoul 440
Cambridge 404
Seattle 401
Dong Ket 398
San Jose 374
Woodbridge 374
Beijing 361
Wilmington 341
Milan 319
Houston 290
Council Bluffs 233
Hefei 224
Los Angeles 221
Ho Chi Minh City 208
Buffalo 190
The Dalles 187
Princeton 181
Rome 178
Florence 172
Mumbai 170
Ann Arbor 158
Lauterbourg 146
Boston 144
Hanoi 133
Altamura 127
Dallas 111
Lawrence 106
Tokyo 100
Melbourne 97
Helsinki 93
Moscow 91
Munich 89
Boardman 87
Shanghai 86
New York 82
Medford 72
Kent 70
Paris 55
San Diego 46
Naples 44
São Paulo 44
Turku 43
Turin 42
West Jordan 40
Bologna 39
Toronto 37
Orem 36
Abidjan 35
Columbus 34
Clifton 32
Chicago 29
Verona 29
Chennai 27
Norwalk 27
Jakarta 26
Philadelphia 26
Redondo Beach 26
Palermo 25
Frankfurt am Main 24
Haiphong 24
Rio de Janeiro 23
Barcelona 22
Da Nang 22
Venice 22
Guangzhou 21
Johannesburg 21
Montreal 21
Bern 20
London 20
Casablanca 19
Washington 19
Amsterdam 17
Auburn Hills 17
Belo Horizonte 17
Camerino 17
Falls Church 17
Hillsboro 17
Brooklyn 16
Figino 16
San Francisco 16
Thái Bình 16
Atlanta 15
Cagliari 15
Izmir 15
Padua 15
Phoenix 15
Baghdad 14
Ferrara 14
Miano 14
Shenzhen 14
Bari 13
Totale 18.125
Salva come PNG Salva come JPEG
Nome #
Adenosine A2B receptors stimulation inhibits oligodendrocyte maturation by interacting with sphingosine kinase/sphingosine 1-phosphate signalling axis in primary purified oligodendrocyte cultures 356
The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. 332
1,2,4-Benzothiadiazine-1,1-dioxide Derivatives as Ionotropic Glutamate Receptor Ligands: Synthesis and Structure–Activity Relationships 300
1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. 284
Synthesis and biological evaluation of novel 9-heteroaryl substituted 7-chloro-4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates (TQX) as AMPA receptor antagonists. 276
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 275
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives. 260
Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazolines as glycine/N-methyl-D-aspartic acid receptor antagonists 256
1,3-DIARYLPYRAZOLO[4,5-C]- AND -[5,4-C]QUINOLIN-4-ONES. 4. SYNTHESIS AND SPECIFIC INHIBITION OF BENZODIAZEPINE RECEPTOR BINDING. 252
The 1,2,4-Triazolo[4,3-a]quinoxalin-1-one Moiety as an Attractive Scaffold to Develop New Potent and Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Pharmacological and Ligand-Receptor Modeling Studies. 251
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold to obtain Potent and Selective Human A3 Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition† 251
Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII 232
3-Hydroxy-1H-quinazoline-2,4-dione as a New Scaffold to Develop Potent and Selective Inhibitors of the Tumor-Associated Carbonic Anhydrases IX and XII 230
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino Derivatives As New Potent and Selective Human A3Adenosine Receptor Antagonists. Molecular Modeling Studies and Pharmacological Evaluation 229
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 228
Adenosine A2B receptors inhibit K+ currents and cell differentiation in cultured oligodendrocyte precursor cells and modulate sphingosine-1-phosphate signaling pathway 225
3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: Molecular modeling and pharmacological studies. 224
1,2,4-Triazolo[4,3-a]pyrazin-3-one as a new scaffold to develop potent adenosine receptor antagonists 221
“1,2,4-TRIAZOLO[1,5-A]QUINOXALINE DERIVATIVES: SYNTHESIS AND BIOLOGICAL EVALUATION AS ADENOSINE RECEPTOR ANTAGONISTS” 217
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 216
A comprehensive strategy in the development of a cyclodextrin-modified microemulsion electrokinetic chromatographic method for the assay of diclofenac and its impurities: Mixture-process variable experiments and quality by design 214
1-Substituted pyrazolo[1,5-c]quinazolines as novel Gly/NMDA receptor antagonists: synthesis, biological evaluation and molecular modeling study 214
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 210
Design, synthesis, and pharmacological characterization of 2‑(2- furanyl)thiazolo[5,4‑d]pyrimidine-5,7-diamine derivatives: new highly potent A2A adenosine receptor inverse agonists with antinociceptive activity 207
Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity 203
Structural Investigation of the 7-Chloro-3-hydroxy-1H-quinazoline-2,4-dione Scaffold to Obtain AMPA and Kainate Receptor Selective Antagonists. Synthesis, Pharmacological and Molecular Modeling Studies 202
1,2,4-triazolo[4,3-a]quinoxalin-1-one as a framework to obtain potent and selective A1, A2A and A3 adenosine receptor antagonists 200
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 199
Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. 197
Functional characterization of a novel adenosine A2B receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus 196
CK1 delta inhibition: an emerging strategy to combat neurodegenerative diseases 195
Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazoline-2-carboxylates as novel excitatory amino acid antagonists 194
4,5-Dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones. Excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity 191
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 189
Development of novel pyridazinone-based adenosine receptor ligands 189
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4-oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists 188
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 188
Structure-activity relationship studies of novel pyrazolo[1,5-c][1,3]benzoxazines: synthesis and benzodiazepine receptor affinity. 184
SYNTHESIS AND BINDING STUDY OF PYRAZOLO[4,5-C][1,8]NAPHTHYRIDINES. 184
SYNTHESIS, BINDING STUDIES, AND STRUCTURE ACTIVITY RELATIONSHIPS OF 1-ARYL- AND 2-ARYL[1]BENZOPYRANOPYRAZOL-4-ONES, CENTRAL BENZODIAZEPINE RECEPTOR LIGANDS. 182
TRICYCLIC HETEROCYCLIC SYSTEMS: PYRAZOLO[5',4':4,5]- AND PYRAZOLO[3',4':4,5]PYRANO[2,3-B]PYRIDINE DERIVATIVES. 181
“3-Hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists” 181
Novel AMPA and kainate receptor antagonists containing the pyrazolo[1,5-c]quinazoline ring system: synthesis and structure-activity relationships 181
Acylsilane-mediated nucleophilic acylation of alfa,beta-unsaturated carbonyl derivatives 181
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2Breceptor 179
2-Aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists 179
Benzodiazepine binding activity of some tricyclic heteroarometic systems to define the hydrogen bonding strength of the proton donors of the receptor site. 178
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates as novel highly selective AMPA receptor antagonists. 178
Inhibition of A2Aadenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455 178
SYNTHESIS OF 1,5-DIARYL-3-METHYL-1H-PYRAZOLO[4,5-C]ISOQUINOLINES AND STUDIES OF BINDING TO SPECIFIC PERIPHERAL BENZODIAZEPINE BINDING SITES. 177
Adenosine Receptor Ligands as Potential Therapeutic Agents for Impaired Wound Healing and Fibrosis 176
Aminopyridine-3,5-carbonitrile core for the design of new adenosine receptor agonists: structural exploration to target the A1 subtype 175
3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies 174
1-(3-Aminophenyl)-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-one: a new selective A2 adenosine receptor antagonist. 173
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies 173
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF 1-AMINOPHTHALAZINIUM SALTS AS GABAA RECEPTOR ANTAGONISTS. 172
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 172
Nuovi tiazoli[5,4-d]pirimidin derivati quali agonisti inversi dei recettori A2A dell'adenosina 172
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 172
3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new potent and selective inhibitors of the tumor-associated carbonic anhydrase IX and XII. 172
2-Aryl-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as new potent adenosine human A2A receptor antagonists 171
STRUCTURE-ACTIVITY RELATIONSHIPS OF 1,2,4-TRIAZOLO[1,5-A]QUINOXALINES AND THEIR 1-DEAZA ANALOGS IMIDAZO[1,2-A]QUINOXALINES AT THE BENZODIAZEPINE RECEPTOR. 170
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as New Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation and Ligand-Receptor Modeling Studies. 170
4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-a] quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors. 169
Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies 168
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A 1 and A 2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 168
Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. 166
Pharmacological Characterization of P626, a Novel Dual Adenosine A2A/A2B Receptor Antagonist, on Synaptic Plasticity and during an Ischemic-like Insult in CA1 Rat Hippocampus 165
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta 165
G protein-coupled receptors as potential drug target: from receptor topology to rational drug design, an in silico approach 164
NOVEL ADENOSINE RECEPTOR LIGANDS: 1,3-DISUBSTITUTED[1]BENZOPYRANO[2,3-C]PYRAZOL-4-ONES. SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS. 164
SYNTHESIS OF SOME 2-ARYL-1,2,4-TRIAZOLO[1,5-C][1,3]BENZOXAZIN-5-ONES AS TOOLS TO DEFINE THE ESSENTIAL PHARMACOPHORIC DESCRIPTORS OF A BENZODIAZEPINE RECEPTOR LIGAND. 163
TRICYCLIC HETEROAROMATIC SYSTEMS. 1,2,4-TRIAZOLO[1,5-A]QUINOXALINE. 163
Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A1 and A2A Receptors, and Efficacy in Animal Models of Depression 163
DIPYRAZOLO[5,4-B:3',4'-D]PYRIDINES. SYNTHESIS, INHIBITION OF BENZODIAZEPINE RECEPTOR BINDING AND STRUCTURE-ACTIVITY RELATIONSHIPS. 160
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 160
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents 160
TRICYCLIC HETEROAROMATIC SYSTEMS. 1,2,3,4-TETRAHYDROPYRAZOLO[4,3-C][1]BENZAZEPIN-1-ONES AS POTENTIAL ANTITUMOR AGENTS. 159
TRICYCLIC HETEROAROMATIC SYSTEMS: SYNTHESIS, [3H]FLUNITRAZEPAM BRAIN MEMBRANE BINDING INHIBITION, AND STRUCTURE-ACTIVITY RELATIONSHIPS OF 2,3-DIHYDRO-2-ARYL-4-R-[1]BENZOPYRANO[4,3-C]PYRAZOL-3-ONES. 159
Piperazine-and piperidine-containing thiazolo[5,4-d]pyrimidine derivatives as new potent and selective adenosine a2a receptor inverse agonists 157
Synthesis and Pharmacological Studies at the Gly/NMDA, AMPA and Kainate Receptors of New Oxazolo[4,5-c]quinolin-4-one derivatives bearing different substituents at position-2 and on the fused benzo ring 156
REACTION OF 1-AMINOPHTHALAZINES WITH A-HALOCARBONYL COMPOUNDS: IMIDAZO-2,1-A]PHTHALAZINES AND THEIR BENZODIAZEPINE RECEPTOR ACTIVITIES. 156
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a New Scaffold To Develop Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand-Receptor Modeling Studies. 156
TRICYCLIC HETEROAROMATIC SYSTEMS. 5H-1,2,4-TRIAZOLO[5,1-C][1,4]BENZODIAZEPINE. 155
TRICYCLIC HETEROAROMATIC SYSTEMS: [1]BENZOPYRANOPYRAZOL-4-ONES AS BENZODIAZEPINE RECEPTOR LIGANDS. 155
THE CORRECT SYNTHESIS OF 2,3-DIHYDRO-2-ARYL-4-R-[1]BENZOPYRANO[4,3-C]PYRAZOLE-3-ONES. 155
Synthesis, glycine/NMDA and AMPA binding activity of some new 2,5,6-trioxopyrazino[1,2,3-de]quinoxalines and of their restricted analogs 2,5-dioxo- and 4,5-dioxoimidazo[1,5,4-de]quinoxalines. 154
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: Synthesis, structure–affinity relationships and molecular modeling studies 154
TRICYCLIC HETEROAROMATIC SYSTEMS. 5H-1,2,3-TRIAZOLO[5,1-C][1,4]BENZODIAZEPINE. 154
Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists. 154
4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives 154
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF 4-CYCLOALKYLAMINO-1,2,4-TRIAZOLO[4,3-A]QUINOXALIN-1-ONE DERIVATIVES AS A1 AND A3 ADENOSINE RECEPTOR ANTAGONISTS. 153
Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders 153
TRICYCLIC HETEROAROMATIC SYSTEMS. SYNTHESIS AND A1 AND A2A ADENOSINE BINDING ACTIVITIES OF SOME 1-ARYL-1,4-DIHYDRO-3-METHYL[1]BENZOPYRANO[2,3-C]PYRAZOL-4-ONES, 1-ARYL-4,9-DIHYDRO-3-METHYL-1H-PYRAZOLO[3,4-B]QUINOLIN-4-ONES, AND 1-ARYL-1H-IMIDAZO[4,5-B]QUINOXALINES. 152
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists. 151
Pyrazoloquinazoline tricyclic system as novel scaffold to design new kinase CK2 inhibitors. 151
New 2-Arylpyrazolo[3,4-c]quinoline Derivatives as Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation and Ligand-Receptor Modeling Studies. 149
Tandem 3D-QSARs Approach as a Valuable Tool To Predict Binding Affinity Data: Design of New Gly/NMDA Receptor Antagonists as a Key Study. 149
Tricyclic heteroaromatic systems. Synthesis and benzodiazepine receptor affinity of 2-substituted-1-benzopyrano[3,4-d]oxazol-4-ones, -thiazol-4-ones, and –imidazol-4-ones. 149
Tricyclic heteroaromatic systems. 1,2,4-triazolo[4,3-a]quinoxalines and 1,2,4-triazino[4,3-a]quinoxalines: synthesis and central benzodiazepine receptor activity. 148
Totale 18.907
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.705
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.705
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.028 0 124 70 56 34 39 37 72 45 52 186 313
2022/20232.832 270 431 139 189 229 524 414 169 305 16 95 51
2023/20241.323 56 117 191 55 54 329 57 197 38 100 74 55
2024/20257.980 251 843 464 1.043 2.471 1.217 126 436 324 231 311 263
2025/20268.608 998 1.175 771 831 827 264 832 401 570 517 227 1.195
2026/2027614 349 265 0 0 0 0 0 0 0 0 0 0
Totale 28.245